HIGHLAND-EUROPE
7.12.2020 13:33:03 CET | Business Wire | Press release
Highland Europe has strengthened its industry-renowned team with the promotion of Jean Tardy-Joubert, Gajan Rajanathan and Ronan Shally to Partner. Tardy-Joubert and Rajanathan joined Highland in 2017/18 from Qatalyst, the San Francisco-based boutique investment bank serving the global tech sector, while Shally has been with the firm since 2014 and is Highland’s Chief Financial Officer. By promoting Gajan, Jean and Ronan, Highland Europe is better positioned than ever to help the founders it backs to achieve their ambitions. Highland Europe is differentiated by a high-touch, collaborative approach to helping companies scale globally.
Highland Europe also announces today that it closed its fourth fund, raising €700M to double-down on its strategy of backing the continent’s most outstanding founder-led teams in software and internet businesses.
Building on a track record of investing in consumer tech brands and software companies such as AMCS, Brandwatch, ContentSquare, Featurespace, GetYourGuide, Huel, Jellysmack, MatchesFashion, Nexthink, PhotoBox, WeTransfer, Zwift and Wolt, the new fund takes Highland Europe’s assets under management to €1.8bn.
Over the past 12 months, the firm has backed seven exceptional founding teams investing nearly €200M in Alkemics, Cobalt, DominoDatalab, Farewill, Meditopia, Modulr and Supermetrics as well as the existing portfolio. Highland Europe’s portfolio companies attracted exceptional external investment appetite with €730M follow-on investment in the last 12 months, some of which fueled seven M&A transactions completed by portfolio companies. Last but not least, the team helped two founder-led teams (Spot and Smartly.io) navigate strategic and private equity interest, resulting in substantial liquidity events.
Just as mission-critical tech and innovation have been instrumental in enabling businesses and individuals to continue functioning during the pandemic, technology looks set to play a key role in an eventual economic recovery. Reflecting this, Highland saw significant commitment from investors, resulting in an oversubscribed €700M fund.
Fergal Mullen, co-founder and partner at Highland Europe, said: “During 2020 we have seen 10-year trends in tech adoption compressed into one year across both consumer and business segments. Software has gone mainstream and it is mission-critical. The opportunity at the growth stage in Europe has never been more evident or more urgent. Highland Europe’s role is to bring capital, our deep network and scaling expertise to companies that can make it all the way to IPO. We have the track record, the team and a highly selective and focused strategy to help Europe’s most promising tech businesses become global leaders.”
‘Growth funding deficit’
Scaling software businesses to become global leaders requires expertise, insight and capital. Europe’s tech companies are proliferating at Seed and Series A, but remain starved of funding at growth stage. Figures from Dealroom.co show that European companies raised 38% of global venture capital at Seed, but this figure dropped to 21% at Series B and 14% at Series C (rounds of €40-100M). Until this is fixed, Europe will not reach its full potential, let alone challenge the dominance of the American and Asian tech giants.
Without good European sources of capital, many promising tech companies will struggle to raise the funds needed to fuel international success. According to one estimate, just one in eight European companies reach scale, compared with one in four in America. Highland Europe is determined to address this massive opportunity with a continued focus on mission-critical growth stage software and consumer technology companies, which have demonstrated compelling market traction and global ambition.
--ENDS--
About Highland Europe
Highland Europe invests in exceptional growth-stage software and internet companies. Active in Europe since 2003 as Highland Capital Partners and formally launched in 2012, Highland Europe has raised over €1.8 billion and has invested in companies such as Adjust, AMCS, Camunda, ContentSquare, Featurespace, GetYourGuide, Huel, Jellysmack, Malwarebytes, MatchesFashion, NewVoiceMedia, Nexthink, Spot, Supermetrics, WeTransfer, Wolt and Zwift. Highland’s collective history of investments across the US, Europe and China includes 46 IPOs and 19 billion-dollar-plus companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201206005032/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom